Amgen, academic centers weigh new FDA pilot to speed early drug trials

Summary

The FDA and stakeholders including Amgen and Memorial Sloan Kettering Cancer Center are developing a pilot program to accelerate first-in-human trials in response to competition from China and Australia in early-phase drug development.